A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy DrugInvestors Business Daily • 09/13/19
Aimmune's stock halted as FDA panel's decision awaited on peanut allergy treatmentMarket Watch • 09/13/19
Why This Peanut Allergy-Focused Biotech Stock Rocketed In Huge VolumeInvestors Business Daily • 09/11/19
Aimmune Therapeutics: A Catalyst-Driven Buy Before Advisory Committee MeetingSeeking Alpha • 08/23/19
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win BigThe Motley Fool • 05/19/19
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19